πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Atea Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Athira Pharma, Inc.

Athira Pharma, Inc. logo
Market Cap: Lowest
Employees: Low

ATH-1017

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.

Tags: Alzheimer's disease, Parkinson's disease, biopharmaceutical, clinical trials, neurodegeneration

Symbol: ATHA

Recent Price: $0.55

Industry: Biotechnology

CEO: Dr. Mark J. Litton M.B.A., Ph.D.

Sector: Healthcare

Employees: 65

Address: 18706 North Creek Parkway, Bothell, WA 98011

Phone: 425 620 8501

Last updated: 2024-12-31

Anixa Biosciences, Inc.

Anixa Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

Chimeric Endocrine Receptor T-cell Technology, Anti-Viral Drug Candidates, Vaccines

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for oncology and infectious diseases, including novel CAR-T technologies for ovarian cancer and vaccines for breast and ovarian cancer.

Tags: CAR-T therapy, COVID-19, anti-viral drugs, biotechnology, infectious diseases, oncology, vaccine development

Symbol: ANIX

Recent Price: $2.50

Industry: Biotechnology

CEO: Dr. Amit Kumar Ph.D.

Sector: Healthcare

Employees: 4

Address: 3150 Almaden Expressway, San Jose, CA 95118

Phone: 408 708 9808

Last updated: 2024-12-31

BioAtla, Inc.

BioAtla, Inc. logo
Market Cap: Low
Employees: Low

BA3011

Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.

Tags: antibody-based therapeutics, biopharmaceutical, cancer, clinical stage, solid tumor

Symbol: BCAB

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Jay M. Short Ph.D.

Sector: Healthcare

Employees: 65

Address: 11085 Torreyana Road, San Diego, CA 92121

Phone: 858 558 0708

Last updated: 2024-12-31

Applied Therapeutics, Inc.

Applied Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

AT-007

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Key products include AT-007 and AT-001.

Tags: biopharmaceutical, cardiovascular disease, clinical trials, diabetic complications, galactosemia

Symbol: APLT

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Shoshana Shendelman Ph.D.

Sector: Healthcare

Employees: 31

Address: 545 Fifth Avenue, New York, NY 10017

Phone: 212 220 9226

Leadership

  • Shoshana Shendelman, Chair, Board of Directors
  • Riccardo Perfetti, Chief Medical Officer
  • Les Funtleyder,
  • Dale Hooks, Chief Commercial Officer
  • Constantine Chinoporos, Chief Business Officer / Chief Operating Officer
  • Joel Marcus,
  • Jay Skyler,
  • Stacy Kanter,
  • Teena Lerner,
  • Donald Landry M.D., Ph.D., Chair, Scientific Advisory Board
  • Roy Freeman M.D.,
  • Roxana Mehran M.D.,
  • Lawrence Steinman M.D.,
  • Gregg Stone M.D.,
  • Donald d'Amico M.D.,
  • Donald Landry, Chair, Scientific Advisory Board
  • Roy Freeman,
  • Roxana Mehran,
  • Lawrence Steinman,
  • Gregg Stone,
  • Donald d'Amico,

Last updated: 2024-12-31

Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

AT-527

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for viral infections, with a lead product candidate AT-527 for COVID-19 treatment.

Tags: COVID-19, antiviral, biopharmaceutical, clinical-stage, therapeutics

Symbol: AVIR

Recent Price: $3.33

Industry: Biotechnology

CEO: Dr. Jean-Pierre Sommadossi Ph.D.

Sector: Healthcare

Employees: 75

Address: 125 Summer Street, Boston, MA 02110

Phone: 857 284 8891

Leadership

  • Jean-Pierre Sommadossi, PhD, FOUNDER, CHAIRMAN & CEO
  • Nancy Agrawal, PhD, Executive VP, Preclinical Development
  • Jonae Barnes, Senior VP, Investor Relations & Corporate Communications
  • Bruce Belanger, PhD, Senior VP, Biostatistics
  • Andrea Corcoran, CFO & Executive VP, Legal
  • Adam DeZure, MD, VP, Clinical Development
  • James MB Evans, PhD, VP, CMC Manufacturing
  • Wayne Foster, EXECUTIVE VP, Chief Accounting Officer
  • Kerry Gagnon, VP, Head of Quality
  • Steven Good, EXECUTIVE VP, PRECLINICAL SCIENCE
  • Janet Hammond, MD, PhD, CHIEF DEVELOPMENT OFFICER
  • Arantxa Horga, MD, Chief Medical Officer
  • Qi Huang, Senior VP, Virology
  • Laura Ishak, Senior VP, Clinical Operations
  • Ariyapadi Krishnaraj, VP, Marketing
  • Adel Moussa, PhD, EXECUTIVE VP, CHEMISTRY
  • Shari Noble, VP, Deputy General Counsel
  • Keith Pietropaolo, Executive VP, Clinical Sciences and Project Management
  • Brian Rowe, VP, Business Development
  • Marc Van Hulle, VP, Finance
  • John Vavricka, CHIEF COMMERCIAL OFFICER
  • Alex Vo, PhD, VP, DMPK
  • Jayanthi Wolf, PhD, Executive VP, Regulatory Affairs
  • Xiao-Jian Zhou, PhD, EXECUTIVE VP, EARLY STAGE DEVELOPMENT

Last updated: 2024-12-31

Vera Therapeutics, Inc.

Vera Therapeutics, Inc. logo
Market Cap: High
Employees: Low

atacicept

Vera Therapeutics, Inc. is a clinical stage biotechnology company focusing on developing and commercializing treatments for serious immunological diseases, including atacicept for immunoglobulin A nephropathy and MAU868 for BK viremia infections.

Tags: MAU868, atacicept, biotechnology, clinical trial, immunological diseases

Symbol: VERA

Recent Price: $42.06

Industry: Biotechnology

CEO: Dr. Marshall W. Fordyce M.D.

Sector: Healthcare

Employees: 72

Address: 8000 Marina Boulevard, Brisbane, CA 94005

Phone: 650 770 0077

Last updated: 2024-12-31

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. logo
Market Cap: High
Employees: Low

APG777, APG808, APG990, APG222

Apogee Therapeutics, Inc. is a biotechnology company developing biologics for the treatment of atopic dermatitis, COPD, and related inflammatory and immunology conditions. Founded in 2022 and based in Waltham, Massachusetts.

Tags: COPD, atopic dermatitis, biologics, biotechnology, clinical stage, immunology, inflammatory

Symbol: APGE

Recent Price: $44.64

Industry: Biotechnology

CEO: Dr. Michael Thomas Henderson M.D.

Sector: Healthcare

Employees: 91

Address: 221 Crescent Street, Waltham, MA 02453

Phone: 650-394-5230

Last updated: 2024-12-31

Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ATRN-119

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.

Tags: DNA damage response, biopharmaceutical, cancer therapeutics, clinical trial

Symbol: APRE

Recent Price: $3.48

Industry: Biotechnology

CEO: Dr. Oren Gilad Ph.D.

Sector: Healthcare

Employees: 7

Address: 535 Boylston St., Boston, MA 02116

Phone: 617-463-9385

Last updated: 2024-12-31

Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

Endoxifen

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for oncology and infectious diseases with key programs in breast cancer and COVID-19 treatment.

Tags: COVID-19, Endoxifen, biopharmaceutical, breast cancer, infectious diseases, oncology

Symbol: ATOS

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Steven C. Quay FCAP, M.D., Ph.D.

Sector: Healthcare

Employees: 12

Address: 107 Spring Street, Seattle, WA 98104

Phone: 206 588 0256

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Astria Therapeutics, Inc.

Astria Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

STAR-0215

Astria Therapeutics, Inc., is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic and immunological diseases in the United States. Its lead product candidate, STAR-0215, is targeting hereditary angioedema.

Tags: allergic diseases, biopharmaceutical, hereditary angioedema, immunological diseases, rare diseases

Symbol: ATXS

Recent Price: $8.88

Industry: Biotechnology

CEO: Ms. Jill C. Milne Ph.D.

Sector: Healthcare

Employees: 59

Address: 100 High Street, Boston, MA 02110

Phone: 617 349 1971

Last updated: 2024-12-31

Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

AV-101

Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for rare cardiopulmonary diseases, with a lead product AV-101 for pulmonary arterial hypertension.

Tags: biopharmaceutical, cardiopulmonary diseases, drug development, pulmonary arterial hypertension

Symbol: AVTE

Recent Price: $2.66

Industry: Biotechnology

CEO: Mr. Timothy P. Noyes M.B.A.

Sector: Healthcare

Employees: 51

Address: 930 Winter Street, Waltham, MA 02116

Phone: 617 443 2400

Last updated: 2024-12-31

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

CC-31244, CC-42344

Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and development of antiviral drugs for tackling serious and chronic viral diseases such as hepatitis C, influenza, coronavirus, and norovirus.

Tags: antiviral, biotechnology, coronavirus, hepatitis C, influenza, norovirus

Symbol: COCP

Recent Price: $3.25

Industry: Biotechnology

CEO: Dr. Sam Lee Ph.D.

Sector: Healthcare

Employees: 12

Address: 19805 North Creek Parkway, Bothell, WA 98011

Phone: 786 459 1831

Leadership

  • Sam Lee, Ph.D., Co-Chief Executive Officer and President
  • James J. Martin, Co-Chief Executive Officer and Chief Financial Officer
  • Roger Kornberg, Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board
  • Steve Rubin, Vice Chairman
  • Phillip Frost, Director
  • Fred Hassan, Director
  • Anthony Japour, President, CEO and Director
  • Richard C. Pfenniger, Jr., Director

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

inupadenant, EOS-448

Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. Their product pipeline includes inupadenant and EOS-448, which are in various phases of clinical trials.

Tags: biopharmaceutical, clinical trials, immuno-oncology, therapeutics

Symbol: ITOS

Recent Price: $7.29

Industry: Biotechnology

CEO: Dr. Michel Detheux Ph.D.

Sector: Healthcare

Employees: 157

Address: 321 Arsenal Street, Cambridge, MA 02472-5710

Phone: 339 217 0161

Leadership

  • Michel DETHEUX, President, Chief Executive Officer
  • Matt CALL, Chief Operating Officer
  • Matthew GALL, Chief Financial Officer
  • Yvonne MCGRATH, Chief Scientific Officer
  • David Feltquate, Chief Medical Officer
  • Philippe BRANTEGEM, Executive Vice President of Human Resources
  • Adi OSOVSKY, Executive Vice President of Legal
  • David HALLAL, Chair of the Board
  • Aaron DAVIS,
  • Jill DESIMONE,
  • David LEE,
  • Tim VAN HAUWERMEIREN,
  • Tony HO,
  • Robert IANNONE,
  • Ann RHOADS,

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation logo
Market Cap: Medium
Employees: Low

AB-729, AB-836, AB-161, AB-101

Arbutus Biopharma Corporation is a biopharmaceutical company that develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. The company's HBV product pipeline includes RNA interference products and oral capsid inhibitors, and it is involved in strategic alliances for research and development.

Tags: HBV, Hepatitis B, RNA interference, SARS-CoV-2, biopharmaceutical, capsid inhibitor, coronaviruses, therapeutics

Symbol: ABUS

Recent Price: $3.20

Industry: Biotechnology

CEO: Mr. Michael J. McElhaugh

Sector: Healthcare

Employees: 73

Address: 701 Veterans Circle, Warminster, PA 18974

Phone: 267 469 0914

Leadership

  • Michael J. McElhaugh, Interim President and Chief Executive Officer and Director
  • Michael J. Sofia PhD, Chief Scientific Officer
  • Karen Sims, MD, PhD, Chief Medical Officer
  • David C. Hastings, Chief Financial Officer
  • Christopher Naftzger, General Counsel and Chief Compliance Officer
  • Lisa Caperelli, Vice President, Investor Relations
  • Shannon Briscoe, SPHR, SHRM-SCP, Vice President, Human Resources
  • Frank Torti, MD, Chairman
  • Daniel Burgess, Independent Director
  • Richard C. Henriques, Independent Director
  • Keith Manchester, MD, Independent Director
  • James Meyers, Independent Director
  • Melissa V. Rewolinski, PhD, Independent Director

Last updated: 2024-12-31

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

N/A

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases, with targets including respiratory syncytial virus, SARS-Co V-2, human metapneumovirus, and hepatitis B virus.

Tags: SARS-Co V-2, biotechnology, hepatitis B virus, liver diseases, pharmaceuticals, respiratory syncytial virus, small molecule drugs, viral infections

Symbol: ENTA

Recent Price: $5.85

Industry: Biotechnology

CEO: Dr. Jay R. Luly Ph.D.

Sector: Healthcare

Employees: 145

Address: 500 Arsenal Street, Watertown, MA 02472

Phone: 617 607 0800

Leadership

  • Jay R. Luly, Ph.D., President, Chief Executive Officer and Director
  • Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
  • Matthew P. Kowalsky, J.D., Chief Legal Officer
  • Brendan Luu, Chief Business Officer
  • Paul J. Mellett, Chief Financial and Administrative Officer
  • Yat Sun Or, Ph.D., Chief Scientific Officer
  • Scott T. Rottinghaus, M.D., Chief Medical Officer
  • Bruce L.A. Carter, Ph.D., Chairman of the Board
  • Mark G. Foletta, Board Member
  • Yujiro S. Hata, Board Member
  • Kristine Peterson, Board Member
  • Lesley Russell, MBChB, MRCPb, Board Member
  • Terry Vance, Board Member

Last updated: 2024-12-31

Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Nana-val

Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for the treatment of virus-associated malignancies, with a lead product candidate Nana-val in clinical trials for Epstein-Barr virus-positive lymphoma and other related conditions.

Tags: EBV+ lymphoma, biotech, clinical trials, oncology, pharmaceuticals, virus-associated malignancies

Symbol: VIRX

Recent Price: $0.16

Industry: Biotechnology

CEO: Mr. Mark Andrew Rothera

Sector: Healthcare

Employees: 40

Address: 2533 South Coast Highway 101, Cardiff-by-the-Sea, CA 92007

Phone: 858 400 8470

Leadership

  • Mark Rothera, President and Chief Executive Officer
  • Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer
  • Ayman Elguindy, Ph.D., Chief Scientific Officer
  • Michael Faerm, MBA, Chief Financial Officer
  • Cheryl Madsen, Senior Vice President, Regulatory
  • Patric Nelson, MBA, Senior Vice President, Business Development & Corporate Strategy
  • Biljana Nadjsombati, Pharm.D., Senior Vice President, Pharmaceutical Development
  • Violetta Akopian, Ph.D., Vice President, Quality Assurance
  • Ruby Cheema, Vice President, Portfolio and Program Management
  • Mark A. McCamish, M.D., Ph.D., Strategic Advisor
  • Roger J. Pomerantz, M.D., Chairman of the Board
  • Jane F. Barlow, M.D., MPH, MBA, Director
  • Flavia Borellini, Ph.D., Director
  • Jane Chung, R.Ph., Director
  • Thomas E. Darcy, CPA, Director
  • Sam Murphy, Ph.D., Director
  • Ivor Royston, M.D., Director
  • Stephen Rubino, Ph.D., MBA, Director
  • Barry J. Simon, M.D., Director
  • Douglas V. Faller, M.D., Ph.D., Scientific Founder and Chairman, Scientific Advisory Board
  • Robert Baiocchi, M.D., Ph.D., Scientific Advisor
  • Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath, Scientific Advisor
  • Carl June, M.D., Scientific Advisor
  • Shannon Kenney, M.D., Scientific Advisor
  • Ronald Levy, M.D., Scientific Advisor
  • Pierluigi Porcu, M.D., Scientific Advisor
  • Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR, Scientific Advisor
  • Lawrence Young, Ph.D., Scientific Advisor

Last updated: 2024-12-31